Cargando…
Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis
The vitamin D receptor (VDR) principally mediates the anticancer activities of vitamin D. Various epidemiological studies have investigated the associations of VDR gene polymorphisms with ovarian cancer; however, the results have been inconclusive. In the current study, we evaluated, in a meta-analy...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691226/ https://www.ncbi.nlm.nih.gov/pubmed/23826116 http://dx.doi.org/10.1371/journal.pone.0066716 |
_version_ | 1782274441941614592 |
---|---|
author | Liu, Yanling Li, Chenglin Chen, Peizhan Li, Xiaoguang Li, Mian Guo, He Li, Jingquan Chu, Ruiai Wang, Hui |
author_facet | Liu, Yanling Li, Chenglin Chen, Peizhan Li, Xiaoguang Li, Mian Guo, He Li, Jingquan Chu, Ruiai Wang, Hui |
author_sort | Liu, Yanling |
collection | PubMed |
description | The vitamin D receptor (VDR) principally mediates the anticancer activities of vitamin D. Various epidemiological studies have investigated the associations of VDR gene polymorphisms with ovarian cancer; however, the results have been inconclusive. In the current study, we evaluated, in a meta-analysis, the association of five common single nucleotide polymorphisms (SNPs) in the VDR gene (ApaI, BsmI, Cdx-2, FokI, and TaqI) with the risk of ovarian cancer. Six eligible studies, with a total of 4,107 cases and 6,661 controls, which evaluated the association of these variants and ovarian cancer risk, were identified from the MEDLINE and PubMed databases. The meta-analysis indicated that FokI was associated with an increased ovarian cancer risk, with a pooled odds ratio (OR) of 1.10 [95% confidence intervals (95% CI) = 1.00–1.20] for CT heterozygotes and 1.16 (95% CI = 1.02–1.30) for TT homozygotes relative to common CC carriers. Carriers of the T allele (also known as the f allele) showed an 11% (pooled OR = 1.11, 95% CI = 1.02–1.21; TT/CT vs. CC) increased risk of ovarian cancer relative to CC carriers. For FokI, no significant heterogeneity between the studies was found (I(2) = 0%, P = 0.62 for the Q test). There was no statistically significant association between the other four variants (ApaI, BsmI, Cdx-2 and TaqI) and risk of ovarian cancer. These data indicate that the polymorphism FokI on the VDR is a susceptibility factor for ovarian cancer. Nevertheless, more studies are warranted to elucidate the underlying mechanisms of the VDR in development of ovarian cancer. |
format | Online Article Text |
id | pubmed-3691226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36912262013-07-03 Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis Liu, Yanling Li, Chenglin Chen, Peizhan Li, Xiaoguang Li, Mian Guo, He Li, Jingquan Chu, Ruiai Wang, Hui PLoS One Research Article The vitamin D receptor (VDR) principally mediates the anticancer activities of vitamin D. Various epidemiological studies have investigated the associations of VDR gene polymorphisms with ovarian cancer; however, the results have been inconclusive. In the current study, we evaluated, in a meta-analysis, the association of five common single nucleotide polymorphisms (SNPs) in the VDR gene (ApaI, BsmI, Cdx-2, FokI, and TaqI) with the risk of ovarian cancer. Six eligible studies, with a total of 4,107 cases and 6,661 controls, which evaluated the association of these variants and ovarian cancer risk, were identified from the MEDLINE and PubMed databases. The meta-analysis indicated that FokI was associated with an increased ovarian cancer risk, with a pooled odds ratio (OR) of 1.10 [95% confidence intervals (95% CI) = 1.00–1.20] for CT heterozygotes and 1.16 (95% CI = 1.02–1.30) for TT homozygotes relative to common CC carriers. Carriers of the T allele (also known as the f allele) showed an 11% (pooled OR = 1.11, 95% CI = 1.02–1.21; TT/CT vs. CC) increased risk of ovarian cancer relative to CC carriers. For FokI, no significant heterogeneity between the studies was found (I(2) = 0%, P = 0.62 for the Q test). There was no statistically significant association between the other four variants (ApaI, BsmI, Cdx-2 and TaqI) and risk of ovarian cancer. These data indicate that the polymorphism FokI on the VDR is a susceptibility factor for ovarian cancer. Nevertheless, more studies are warranted to elucidate the underlying mechanisms of the VDR in development of ovarian cancer. Public Library of Science 2013-06-24 /pmc/articles/PMC3691226/ /pubmed/23826116 http://dx.doi.org/10.1371/journal.pone.0066716 Text en © 2013 Liu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Liu, Yanling Li, Chenglin Chen, Peizhan Li, Xiaoguang Li, Mian Guo, He Li, Jingquan Chu, Ruiai Wang, Hui Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis |
title | Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis |
title_full | Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis |
title_fullStr | Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis |
title_full_unstemmed | Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis |
title_short | Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis |
title_sort | polymorphisms in the vitamin d receptor (vdr) and the risk of ovarian cancer: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691226/ https://www.ncbi.nlm.nih.gov/pubmed/23826116 http://dx.doi.org/10.1371/journal.pone.0066716 |
work_keys_str_mv | AT liuyanling polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis AT lichenglin polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis AT chenpeizhan polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis AT lixiaoguang polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis AT limian polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis AT guohe polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis AT lijingquan polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis AT churuiai polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis AT wanghui polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis |